Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, esophageal, and gastroesophageal junction cancers.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a case-based session ...

The leading Advanced Melanoma Companies such as OncoSec Medical, Immunocore, Sanofi, TILT Biotherapeutics, Novartis ...

A combination immunotherapy may help cure a majority of patients with melanoma -- a deadly skin cancer -- that has spread to ...

Liver Cancer Therapeutics Market Growth is Driven by Advancements in Precision Medicine, Immunotherapy and Growing Global Incidence.Pune, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Liver Cancer Therapeutics ...

(HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding nivolumab to ...

During a Case-Based Roundtable® event, Evan J. Lipson, MD, moderated a discussion on the tolerability of immunotherapy in metastatic melanoma and when to stop therapy.

AVEO Oncology, an LG Chem company ("AVEO"), is a biopharmaceutical company that is trying to provide differentiated solutions to improve cancer patients lives, presented two posters during the 2025 ...

SYDNEY: A groundbreaking Australian clinical trial has shown that a majority of melanoma patients whose cancer has spread to ...